GNR 047
Alternative Names: GNR-047Latest Information Update: 05 Sep 2023
Price :
$50 *
At a glance
- Originator International Biotechnology Center Generium
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action CD19 antigen inhibitors; CD3 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Haematological malignancies in Russia (Parenteral) (Generium pipeline, September 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Haematological-malignancies in Russia (Parenteral)
- 27 Apr 2016 Preclinical trials in Haematological malignancies in Russia (Parenteral) before April 2016